An immunoassay to detect human müllerian inhibiting substance in males and females during normal development.
about
Biomarkers for assessing reproductive development and health: Part 1--Pubertal development.Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceFertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessmentAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implicationsMullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivoAMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapyA pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancerMullerian inhibiting substance binding and uptake.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessEndometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceMullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma modelMeasurement of serum anti-Müllerian hormone concentration in female dogs and cats before and after ovariohysterectomy.Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumorsThe physiology and clinical utility of anti-Mullerian hormone in women.Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivoMüllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodentsPrediction of reproductive outcomes according to different serum anti-Müllerian hormone levels in females undergoing intracystoplasmic sperm injectionTesticular dysgenesis does not affect expression of anti-müllerian hormone by Sertoli cells in premeiotic seminiferous tubulesAAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerFertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunityPhotoperiod-dependent modulation of anti-Müllerian hormone in female Siberian hamsters, Phodopus sungorus.Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.The Anti-Mullerian hormone and ovarian cancer.Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response.The utility of measuring anti-Müllerian hormone in predicting menopause.New AMH assay allows rapid point of care measurements of ovarian reserve.Clinical utility of different anti-Müllerian hormone - AMH assays for the purpose of pregnancy prediction.Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancerMullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.Regulation of sexual dimorphism in mammals.Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability.Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.Anti-Müllerian hormone concentrations in maternal serum during pregnancy.Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?
P2860
Q24810734-38EB3271-72EA-41BE-BB21-514E870351E1Q26829747-FCD87153-8EE2-4CED-9EE9-2583A87F5048Q28077710-3CE9FFF5-2A95-46E1-9B03-DB554993C9D4Q28239980-0DE637E8-5423-4797-90E2-144BB85F36C7Q28577022-C55B6DAA-EA30-4BC0-8C39-06887DA0F76AQ30353654-6D6880ED-BB5E-4D67-871E-278DF86B0FE0Q30435881-480BBE38-01EE-4FE1-B408-6FEEB9318C79Q33202377-BD32D9EF-1860-4067-A904-79DA68993714Q33250633-FB01D364-69AB-4FAB-9810-EEBEB105CE62Q33716008-01040D31-57CE-440C-850D-4EA3F1786E64Q33897273-DB4431B2-CF90-4923-A115-42418A156ED0Q33927553-F0E35855-3A20-4679-B267-B8629FD0B151Q34215276-17C4BEE5-B9EF-4287-8048-7D79F4B76F42Q34246272-F8F3C9AB-B64C-429C-848D-C2B4A7A2BA4CQ34398233-D26179DC-488A-4A04-A2FC-6FE4B6CE9BEDQ34713416-457B42D8-CEB3-4CC8-A037-BA48CB382D25Q34733985-3F8C9179-00D7-4CAC-9899-D08F241CC939Q34999705-134518F0-7AA4-446A-BE4D-849B3B3C0C84Q35773619-0223A0F0-9FDF-49F6-B6E3-F1AA881DA56CQ35961381-B7ACC174-42C3-4956-A745-349D63F7CC58Q35966481-66AD011B-BDFF-45A9-9093-94A86B996090Q36082015-6969A6AA-1769-4FCB-BF2F-FA276C1D93F4Q36593625-33CA1F06-02CF-4983-AF56-711B2B418D97Q36637142-F08E6A62-AE03-46EC-8474-0119B940D742Q36703428-98AB38F5-8E9B-4F69-AA3B-6F7D44E50936Q37372670-A229D584-771D-4EAD-8791-95BB1EBA5D39Q37693327-B90CB011-92F7-471F-94B4-6BA11B60C5ABQ37707380-2488901D-36FD-4DD8-86B3-8D37D1E818ECQ38285639-A558B9A5-574B-462F-80F1-6F32E4159E41Q38407283-4ED20CFE-53D9-4537-BCBF-57949823491CQ38812461-9B885BBB-BEE9-400B-9A92-BBE96F7BABDAQ38817588-C476C567-87C7-42B6-861C-87050F003BC7Q39651067-7F4281FD-9552-4F68-8175-EA9E2864624AQ40394248-6CBE2BF3-4B8C-4449-AF0C-1771C134EB40Q40859015-6DA8417E-8F01-4B42-ACE8-399420AF3383Q41697429-5942F039-6B1F-4050-A1F8-47E9DD29F7ABQ44462687-6B4C2FF0-1D7A-4457-AC2E-E29B434C8279Q45086482-8E36A6CE-174B-4F04-8639-9F7482C684FAQ45285273-894DDB92-9D68-4D48-A4F9-D2641BE28B9CQ47170320-D7E78CD6-E760-4DFB-A1B1-4541544AF2DC
P2860
An immunoassay to detect human müllerian inhibiting substance in males and females during normal development.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
An immunoassay to detect human ...... les during normal development.
@en
An immunoassay to detect human ...... les during normal development.
@nl
type
label
An immunoassay to detect human ...... les during normal development.
@en
An immunoassay to detect human ...... les during normal development.
@nl
prefLabel
An immunoassay to detect human ...... les during normal development.
@en
An immunoassay to detect human ...... les during normal development.
@nl
P2093
P356
P1476
An immunoassay to detect human ...... les during normal development.
@en
P2093
Donahoe PK
MacLaughlin DT
Pepinsky RB
P356
10.1210/JCEM-70-1-16
P407
P577
1990-01-01T00:00:00Z